Senior insider sale
Chief Scientific Officer at NURIX THERAPEUTICS, INC. — senior position signals high conviction
$157.6K
8.61K shares
What this filing means
HANSEN GWENN plans to sell 8.61K shares of NURIX THERAPEUTICS, INC. valued at approximately $157.6K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/25/2026ACC: 0001950047-26-006499
Officer· Chief Scientific Officer
Since Jul 2020
8.61K
Shares to sell
$157.6K
Approx. market value
5.39K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months1
Restricted Stock Units
N/A
4/30/2026
5.39KTotal acquired5.39K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
4/30/2026 | Restricted Stock Units N/A | 5.39K | — |
| Total | 5.39K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
3.21K
Market value
$53.5K
4/30/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
5.39K
Market value
$104.1K
6/25/2026
Total
Units
8.61K
Value
$157.6K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
4/30/2026 | 3.21K | $53.5K | — | Completed |
| Planned — Approximate Date | ||||
6/25/2026 | 5.39K | $104.1K | NASDAQ | Planned |
| Total | 8.61K | $157.6K | ||